

Michael P Pender

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8996574/publications.pdf>

Version: 2024-02-01

157
papers

6,635
citations

53794

45
h-index

74163

75
g-index

163
all docs

163
docs citations

163
times ranked

7523
citing authors

#	ARTICLE	IF	CITATIONS
1	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. <i>Journal of Neurology</i> , 2022, 269, 836-845.	3.6	5
2	High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1112-1124.	3.0	10
3	Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein-Barr Virus-Specific T Cell Therapy. <i>Frontiers in Neurology</i> , 2021, 12, 652811.	2.4	18
4	Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110197.	1.0	9
5	Developing a clinical-environmental-genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. <i>Brain Communications</i> , 2021, 3, fcab288.	3.3	7
6	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020, 26, 296-310.	6.7	178
7	Reduced $\text{I}\kappa\text{B}\alpha$ Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosis: A Possible Cause of Constitutive NF- κB Activation. <i>Journal of Clinical Medicine</i> , 2020, 9, 2534.	2.4	2
8	Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types. <i>Frontiers in Immunology</i> , 2020, 11, 1891.	4.8	14
9	Hypothesis: bipolar disorder is an Epstein-Barr virus-driven chronic autoimmune disease implications for immunotherapy. <i>Clinical and Translational Immunology</i> , 2020, 9, e1116.	3.8	7
10	A Higher Mediterranean Diet Score, Including Unprocessed Red Meat, Is Associated with Reduced Risk of Central Nervous System Demyelination in a Case-Control Study of Australian Adults. <i>Journal of Nutrition</i> , 2019, 149, 1385-1392.	2.9	36
11	Increased constitutive activation of NF- κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2018, 320, 111-116.	2.3	13
12	Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course. <i>Frontiers in Neurology</i> , 2018, 9, 16.	2.4	30
13	Reported Changes in Dietary Behavior Following a First Clinical Diagnosis of Central Nervous System Demyelination. <i>Frontiers in Neurology</i> , 2018, 9, 161.	2.4	21
14	Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset. <i>Frontiers in Neurology</i> , 2018, 9, 418.	2.4	8
15	Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. <i>JCI Insight</i> , 2018, 3, .	5.0	105
16	Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. <i>Clinical and Translational Immunology</i> , 2017, 6, e126.	3.8	90
17	Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638.	1.9	108
18	Stressful life events and the risk of initial central nervous system demyelination. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1000-1007.	3.0	14

#	ARTICLE	IF	CITATIONS
19	Reactivity to Novel Autoantigens in Patients with Coexisting Central Nervous System Demyelinating Disease and Autoimmune Thyroid Disease. <i>Frontiers in Immunology</i> , 2017, 8, 514.	4.8	8
20	Higher intake of omega-3 polyunsaturated fatty acids is associated with a decreased risk of a first clinical diagnosis of central nervous system demyelination: Results from the Ausimmune Study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 884-892.	3.0	80
21	Population attributable fractions and joint effects of key risk factors for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 461-469.	3.0	59
22	Epstein-Barr virus-specific adoptive immunotherapy: a new horizon for multiple sclerosis treatment?. <i>Immunotherapy</i> , 2014, 6, 659-661.	2.0	6
23	Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1541-1544.	3.0	67
24	Deficiency of CD8 ⁺ effector memory T cells is an early and persistent feature of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1825-1832.	3.0	57
25	Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. <i>Clinical and Translational Immunology</i> , 2014, 3, e27.	3.8	120
26	Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. <i>Journal of Neuroimmunology</i> , 2014, 269, 68-75.	2.3	19
27	Vitamin D status: Multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 136, 300-308.	2.5	78
28	Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1355-1358.	3.0	17
29	Occupational Exposure and Risk of Central Nervous System Demyelination. <i>American Journal of Epidemiology</i> , 2013, 177, 954-961.	3.4	17
30	Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. <i>Clinical and Experimental Immunology</i> , 2013, 172, 466-474.	2.6	17
31	The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: The Ausimmune study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1717-1725.	3.0	30
32	Sun Exposure over a Lifetime in Australian Adults from Latitudinally Diverse Regions. <i>Photochemistry and Photobiology</i> , 2013, 89, 737-744.	2.5	22
33	Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 13667-13679.	4.1	17
34	CD8 T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 353-354.	1.9	29
35	CD8 ⁺ T cells far predominate over CD4 ⁺ T cells in healthy immune response to Epstein-Barr virus infected lymphoblastoid cell lines. <i>Blood</i> , 2012, 120, 5085-5087.	1.4	6
36	Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29,000 subjects: Figure 1. <i>Journal of Medical Genetics</i> , 2012, 49, 558-562.	3.2	31

#	ARTICLE	IF	CITATIONS
37	Adherence to <sc>MRI</sc> protocol consensus guidelines in multiple sclerosis: An <sc>A</sc>ustralian multi-centre study. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 594-598.	1.8	14
38	CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune Diseases, 2012, 2012, 1-16.	0.6	195
39	Epstein-Barr virus in the multiple sclerosis brain - An evasive culprit. Multiple Sclerosis and Related Disorders, 2012, 1, 61-63.	2.0	0
40	The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis. Neuroscientist, 2011, 17, 351-367.	3.5	113
41	The role of latitude, ultraviolet radiation exposure and vitamin D in childhood asthma and hayfever: an Australian multicenter study. Pediatric Allergy and Immunology, 2011, 22, 327-333.	2.6	78
42	Decreased CD8+T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes. BMC Neurology, 2011, 11, 95.	1.8	14
43	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology, 2011, 70, 897-912.	5.3	314
44	Latitudinal variation in incidence and type of first central nervous system demyelinating events. Multiple Sclerosis Journal, 2010, 16, 398-405.	3.0	80
45	Investigation of the [A]8 and C1236T genetic variations within the human toll-like receptor 3 gene for association with multiple sclerosis. Neurological Research, 2010, 32, 438-441.	1.3	4
46	Strains of Epstein-Barr virus infecting multiple sclerosis patients. Multiple Sclerosis Journal, 2010, 16, 643-651.	3.0	21
47	Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. Multiple Sclerosis Journal, 2009, 15, 763-766.	3.0	10
48	Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?. Brain, 2009, 132, 3196-3198.	7.6	30
49	Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmunity Reviews, 2009, 8, 563-568.	5.8	60
50	An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. Brain Research, 2009, 1255, 148-152.	2.2	12
51	Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nature Genetics, 2009, 41, 824-828.	21.4	501
52	CTLA-4 single-nucleotide polymorphisms in a Caucasian population with schizophrenia. Brain, Behavior, and Immunity, 2009, 23, 347-350.	4.1	16
53	Study of leukemia inhibitory factor polymorphism within an Australian multiple sclerosis population. Journal of the Neurological Sciences, 2009, 280, 62-64.	0.6	0
54	Associations between Silicone Skin Cast Score, Cumulative Sun Exposure, and Other Factors in the Ausimmune Study: A Multicenter Australian Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2887-2894.	2.5	52

#	ARTICLE	IF	CITATIONS
55	Is Wikipedia unsuitable as a clinical information resource for medical students?. <i>Medical Teacher</i> , 2009, 31, 1095-6.	1.8	13
56	Restricted diffusion on MR imaging of an acute cerebral lesion. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 456.	1.5	1
57	Myelin proteolipid protein: An effective autoantigen and target of autoimmunity in multiple sclerosis. <i>Journal of Autoimmunity</i> , 2008, 31, 281-287.	6.5	40
58	Apneusis responding to buspirone in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 705-707.	3.0	11
59	Correlation of Blood T Cell and Antibody Reactivity to Myelin Proteins with HLA Type and Lesion Localization in Multiple Sclerosis. <i>Journal of Immunology</i> , 2008, 180, 6402-6410.	0.8	39
60	Observational analytic studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. <i>Multiple Sclerosis Journal</i> , 2007, 13, 827-839.	3.0	68
61	Dysarthria and dysphagia due to the opercular syndrome in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 817-819.	3.0	18
62	Allelic variation investigation of the estrogen receptor within an Australian multiple sclerosis population. <i>Journal of the Neurological Sciences</i> , 2007, 252, 9-12.	0.6	6
63	No association between MTHFR A1298C and MTRR A66G polymorphisms, and MS in an Australian cohort. <i>Journal of the Neurological Sciences</i> , 2007, 252, 49-52.	0.6	23
64	Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. <i>Journal of Neuroimmunology</i> , 2007, 191, 26-38.	2.3	17
65	Immunology of multiple sclerosis. <i>Current Allergy and Asthma Reports</i> , 2007, 7, 285-292.	5.3	79
66	Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. <i>Brain Research Bulletin</i> , 2006, 69, 327-331.	3.0	23
67	T-cell apoptosis in human glioblastoma multiforme: Implications for immunotherapy. <i>Journal of Neuroimmunology</i> , 2006, 175, 59-68.	2.3	39
68	Lower motor neuron weakness after diving-related decompression. <i>Neurology</i> , 2006, 66, 451-452.	1.1	0
69	Intestinal pseudo-obstruction complicating multiple sclerosis. <i>Internal Medicine Journal</i> , 2005, 35, 191-192.	0.8	5
70	Immune dysregulation and self-reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?. <i>Immunology and Cell Biology</i> , 2005, 83, 9-17.	2.3	127
71	CSF testing for multiple sclerosis. <i>Lancet Neurology</i> , The, 2005, 4, 522-523.	10.2	2
72	Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. <i>Journal of Neuroimmunology</i> , 2005, 160, 162-169.	2.3	59

#	ARTICLE	IF	CITATIONS
73	Oligodendrocyte apoptosis before immune attack in multiple sclerosis?. <i>Annals of Neurology</i> , 2005, 57, 158-158.	5.3	6
74	Multiple Sclerosis with Idiopathic Dilated Cardiomyopathy: A Case Report. <i>European Neurology</i> , 2005, 53, 214-215.	1.4	5
75	VARIATION IN THE VITAMIN D RECEPTOR GENE IS ASSOCIATED WITH MULTIPLE SCLEROSIS IN AN AUSTRALIAN POPULATION. <i>Journal of Neurogenetics</i> , 2005, 19, 25-38.	1.4	114
76	Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barré syndrome. <i>Journal of Clinical Neuroscience</i> , 2005, 12, 409-415.	1.5	27
77	Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis. <i>Inflammation and Allergy: Drug Targets</i> , 2004, 3, 279-290.	3.1	32
78	Investigation of a neuronal nitric oxide synthase gene (NOS1) polymorphism in a multiple sclerosis population. <i>Journal of the Neurological Sciences</i> , 2004, 218, 25-28.	0.6	9
79	Investigation of an inducible nitric oxide synthase gene (NOS2A) polymorphism in a multiple sclerosis population. <i>Brain Research Bulletin</i> , 2004, 64, 9-13.	3.0	15
80	Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. <i>Journal of Autoimmunity</i> , 2004, 22, 345-352.	6.5	31
81	The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?. <i>Journal of Clinical Neuroscience</i> , 2004, 11, 689-692.	1.5	35
82	Epstein-Barr Virus and Autoimmunity. , 2004, , 163-170.		1
83	Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. <i>Trends in Immunology</i> , 2003, 24, 584-588.	6.8	243
84	Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2003, 10, 63-66.	1.5	57
85	Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects. <i>Internal Medicine Journal</i> , 2002, 32, 554-563.	0.8	26
86	Cyclosporin A treatment modulates cytokine mRNA expression by inflammatory cells extracted from the spinal cord of rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein. <i>Journal of the Neurological Sciences</i> , 2001, 187, 7-16.	0.6	11
87	The use of interferon beta at the time of initial diagnosis of multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2001, 8, 381-382.	1.5	1
88	Apoptosis of inflammatory cells in immune control of the nervous system: Role of glia. <i>Glia</i> , 2001, 36, 137-144.	4.9	122
89	Rapid entry and downregulation of T cells in the central nervous system during the reinduction of experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001, 112, 15-27.	2.3	27
90	Autoimmune hypothyroidism associated with interferon beta treatment in two patients with multiple sclerosis. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 278-279.	0.5	16

#	ARTICLE	IF	CITATIONS
91	A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. <i>Acta Neuropathologica</i> , 2000, 100, 174-182.	7.7	67
92	4: Multiple sclerosis. <i>Medical Journal of Australia</i> , 2000, 172, 556-562.	1.7	17
93	Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects. <i>Journal of Immunology</i> , 2000, 165, 5322-5331.	0.8	62
94	B cell Apoptosis in the Central Nervous System in Experimental Autoimmune Encephalomyelitis: Roles of B cell CD95, CD95L and Bcl-2 Expression. <i>Journal of Autoimmunity</i> , 2000, 14, 195-204.	6.5	24
95	The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. <i>Journal of Clinical Neuroscience</i> , 2000, 7, 434-437.	1.5	102
96	Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. <i>Immunology and Cell Biology</i> , 1999, 77, 216-223.	2.3	68
97	Spinal cord disease due to melioidosis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1999, 93, 175-176.	1.8	13
98	Survival and mitosis of myelinating oligodendrocytes in experimental autoimmune encephalomyelitis: an immunocytochemical study with Rip antibody. <i>Acta Neuropathologica</i> , 1999, 98, 39-47.	7.7	11
99	Effects of cyclosporin A treatment on clinical course and inflammatory cell apoptosis in experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. <i>Journal of Neuroimmunology</i> , 1999, 97, 60-69.	2.3	21
100	Recent progress in the diagnosis and treatment of multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 367-372.	1.5	7
101	Immunoneurology. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 272-273.	1.5	0
102	BalÃ³'s concentric sclerosis in a woman from Papua New Guinea. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 46-48.	1.5	4
103	Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. <i>Annals of Neurology</i> , 1998, 44, 980-983.	5.3	137
104	Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. <i>European Journal of Immunology</i> , 1998, 28, 1626-1635.	2.9	36
105	The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1998, 82, 47-55.	2.3	63
106	Cytokine expression by inflammatory cells obtained from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein and adjuvants. <i>Journal of Neuroimmunology</i> , 1998, 88, 30-38.	2.3	25
107	Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. <i>Lancet, The</i> , 1998, 351, 978-981.	13.7	99
108	Microglia are more susceptible than macrophages to apoptosis in the central nervous system in experimental autoimmune encephalomyelitis through a mechanism not involving Fas (CD95). <i>International Immunology</i> , 1998, 10, 935-941.	4.0	61

#	ARTICLE	IF	CITATIONS
109	Increased Apoptosis of T Lymphocytes and Macrophages in the Central and Peripheral Nervous Systems of Lewis Rats with Experimental Autoimmune Encephalomyelitis Treated with Dexamethasone. Journal of Neuropathology and Experimental Neurology, 1997, 56, 58-69.	1.7	59
110	Recent advances in the understanding, diagnosis and management of multiple sclerosis. Australian and New Zealand Journal of Medicine, 1996, 26, 157-161.	0.5	2
111	A study of human T-cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. Journal of Neuroimmunology, 1996, 70, 65-74.	2.3	18
112	Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V β 28.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V β 28.2+ cells. Journal of Neuroimmunology, 1996, 70, 93-101.	2.3	44
113	Progressive visual loss: an unusual presentation of multiple sclerosis. Journal of Clinical Neuroscience, 1996, 3, 264-267.	1.5	8
114	Interferon beta in the management of multiple sclerosis. Australian and New Zealand Journal of Medicine, 1996, 26, 343-343.	0.5	0
115	A simple technique for flat osmicating and flat embedding of immunolabelled vibratome sections of the rat spinal cord for light and electron microscopy. Journal of Neuroscience Methods, 1996, 65, 51-54.	2.5	5
116	Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. Brain, 1995, 118, 1073-1073.	7.6	0
117	Restoration of conduction in the spinal roots correlates with clinical recovery from experimental autoimmune encephalomyelitis. Muscle and Nerve, 1995, 18, 1093-1100.	2.2	7
118	The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathologica, 1995, 89, 527-531.	7.7	26
119	Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. International Immunology, 1995, 7, 967-973.	4.0	62
120	An introduction to neuroimmunology. , 1995, , 14-25.		5
121	Experimental autoimmune encephalomyelitis. , 1995, , 26-88.		12
122	Acute disseminated encephalomyelitis. , 1995, , 155-165.		5
123	The stiff-man syndrome. , 1995, , 166-176.		2
124	Paraneoplastic neurological disorders. , 1995, , 327-344.		0
125	The proximal peripheral nervous system is a major site of demyelination in experimental autoimmune encephalomyelitis induced in the Lewis rat by a myelin basic protein-specific T cell clone. Acta Neuropathologica, 1995, 89, 527-531.	7.7	0
126	Apoptotic elimination of V β 28.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of V β 28.2+ encephalitogenic T cells. European Journal of Immunology, 1994, 24, 2609-2617.	2.9	117

#	ARTICLE	IF	CITATIONS
127	Clinical and histological findings in proteolipid protein-induced experimental autoimmune encephalomyelitis (EAE) in the lewis rat. Distribution of demyelination differs from that in EAE induced by other antigens. <i>Journal of the Neurological Sciences</i> , 1994, 123, 154-161.	0.6	33
128	Inflammatory cells, microglia and MHC class II antigen-positive cells in the spinal cord of Lewis rats with acute and chronic relapsing experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1994, 51, 153-167.	2.3	41
129	Macrophage Apoptosis in the Central Nervous System in Experimental Autoimmune Encephalomyelitis. <i>Journal of Autoimmunity</i> , 1994, 7, 145-152.	6.5	74
130	Conduction abnormalities are restricted to the central nervous system in experimental autoimmune encephalomyelitis induced by inoculation with proteolipid protein but not with myelin basic protein. <i>Brain</i> , 1994, 117, 975-986.	7.6	17
131	Neurological signs in inflammatory demyelination. <i>Annals of Neurology</i> , 1993, 33, 559-559.	5.3	0
132	Cervical self-manipulation and stroke. <i>Medical Journal of Australia</i> , 1993, 158, 290-290.	1.7	4
133	Acute transverse myelitis after tetanus toxoid vaccination. <i>Lancet, The</i> , 1992, 339, 1111-1112.	13.7	31
134	Apoptosis of CD4 ⁺ T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: Its possible implications for recovery and acquired tolerance. <i>Journal of Autoimmunity</i> , 1992, 5, 401-410.	6.5	114
135	Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: An immunocytochemical and flow cytometric study. <i>Journal of the Neurological Sciences</i> , 1992, 113, 177-186.	0.6	30
136	Neuropathological findings in chronic relapsing experimental allergic neuritis induced in the Lewis rat by inoculation with intradural root myelin and treatment with low dose cyclosporin A. <i>Neuropathology and Applied Neurobiology</i> , 1992, 18, 171-187.	3.2	11
137	Focal conduction block in the dorsal root ganglion in experimental allergic neuritis. <i>Annals of Neurology</i> , 1992, 31, 27-33.	5.3	4
138	Apoptosis in the nervous system in experimental allergic encephalomyelitis. <i>Journal of the Neurological Sciences</i> , 1991, 104, 81-87.	0.6	234
139	Cronkhite-Canada syndrome associated with peripheral neuropathy. <i>Australian and New Zealand Journal of Medicine</i> , 1991, 21, 379-379.	0.5	6
140	Improvement in chronic hepatocerebral degeneration following liver transplantation. <i>Gastroenterology</i> , 1990, 98, 1079-1082.	1.3	88
141	The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A. <i>Acta Neuropathologica</i> , 1990, 80, 172-183.	7.7	49
142	Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. <i>Journal of the Neurological Sciences</i> , 1990, 97, 163-171.	0.6	42
143	The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. <i>Journal of Neuroimmunology</i> , 1990, 28, 131-140.	2.3	45
144	Demyelination and early remyelination in experimental allergic encephalomyelitis passively transferred with myelin basic protein-sensitized lymphocytes in the Lewis rat. <i>Journal of Neuroimmunology</i> , 1989, 25, 125-142.	2.3	28

#	ARTICLE	IF	CITATIONS
145	Hypothermia due to an ascending impairment of shivering in hyperacute experimental allergic encephalomyelitis in the Lewis rat. <i>Journal of the Neurological Sciences</i> , 1989, 94, 231-240.	0.6	15
146	Assessment of Demyelination in Glycol Methacrylate Sections: A New Protocol for Cresyl Fast Violet Staining. <i>Biotechnic & Histochemistry</i> , 1989, 64, 163-167.	0.4	13
147	CONNECTIVE TISSUE DISEASE MIMICKING MULTIPLE SCLEROSIS. <i>Australian and New Zealand Journal of Medicine</i> , 1989, 19, 469-472.	0.5	12
148	AN INTRACRANIAL ARTERIOVENOUS MALFORMATION AND PALATAL MYOCLONUS RELATED TO PSEUDOXANTHOMA ELASTICUM. <i>Australian and New Zealand Journal of Medicine</i> , 1989, 19, 141-143.	0.5	11
149	The pathophysiology of myelin basic protein-induced acute experimental allergic encephalomyelitis in the Lewis rat. <i>Journal of the Neurological Sciences</i> , 1988, 86, 277-289.	0.6	50
150	The pathophysiology of acute experimental allergic encephalomyelitis induced by whole spinal cord in the Lewis rat. <i>Journal of the Neurological Sciences</i> , 1988, 84, 209-222.	0.6	34
151	Demyelination of the Peripheral Nervous System Causes Neurologic Signs in Myelin Basic Protein-Induced Experimental Allergic Encephalomyelitis.. <i>Annals of the New York Academy of Sciences</i> , 1988, 540, 732-734.	3.8	13
152	Demyelination and neurological signs in experimental allergic encephalomyelitis. <i>Journal of Neuroimmunology</i> , 1987, 15, 11-24.	2.3	53
153	Involvement of the dorsal root ganglion in acute experimental allergic encephalomyelitis in the Lewis rat. <i>Journal of the Neurological Sciences</i> , 1986, 72, 231-242.	0.6	33
154	Ascending impairment of nociception in rats with experimental allergic encephalomyelitis. <i>Journal of the Neurological Sciences</i> , 1986, 75, 317-328.	0.6	58
155	Conduction block due to demyelination at the ventral root exit zone in experimental allergic encephalomyelitis. <i>Brain Research</i> , 1986, 367, 398-401.	2.2	23
156	A simple method for high resolution light microscopy of nervous tissue. <i>Journal of Neuroscience Methods</i> , 1985, 15, 213-218.	2.5	16
157	Conduction block in the peripheral nervous system in experimental allergic encephalomyelitis. <i>Nature</i> , 1982, 296, 860-862.	27.8	35